Effect of nebulized epoprostenol (prostacyclin) on exhaled nitric oxide in patients with pulmonary hypertension due to congenital heart disease and in normal controls

1999 ◽  
Vol 97 (1) ◽  
pp. 99 ◽  
Author(s):  
Ian A. FORREST ◽  
Therese SMALL ◽  
Paul A. CORRIS
Keyword(s):  
Nitric Oxide ◽  
Congenital Heart Disease ◽  
Pulmonary Hypertension ◽  
Heart Disease ◽  
Congenital Heart ◽  
Exhaled Nitric Oxide ◽  
Normal Controls

Effect of nebulized epoprostenol (prostacyclin) on exhaled nitric oxide in patients with pulmonary hypertension due to congenital heart disease and in normal controls

1999 ◽  
Vol 97 (1) ◽  
pp. 99-102 ◽  
Author(s):  
Ian A. FORREST ◽  
Therese SMALL ◽  
Paul A. CORRIS
Keyword(s):  
Nitric Oxide ◽  
Congenital Heart Disease ◽  
Pulmonary Hypertension ◽  
Heart Disease ◽  
Congenital Heart ◽  
Normal Subjects ◽  
Exhaled Nitric Oxide ◽  
Chemiluminescence Method ◽  
Significant Difference ◽  
Normal Controls

Inhaled epoprostenol (prostacyclin) may be used in the treatment of severe pulmonary hypertension, improving oxygenation and reducing pulmonary artery pressures. We have observed symptomatic benefits of epoprostenol in patients with congenital heart disease that extend beyond acute haemodynamic effects of the drug, which has a short biological half-life. The aim of this study was to examine the effects of epoprostenol in patients and normal subjects on exhaled nitric oxide (eNO), based on the hypothesis that the drug may alter the resting vasoconstrictor/vasodilator balance. Nine patients with pulmonary hypertension complicating left-to-right cardiac shunts and nine healthy controls received 100 µg of nebulized epoprostenol. Exhaled eNO was measured, using a chemiluminescence method, before, immediately after and 18 h after nebulization. There was no significant difference between the two groups in baseline eNO or eNO immediately following nebulized epoprostenol. Epoprostenol produced a delayed elevation in eNO 18 h after nebulization in patients, but not in normal controls. This study supports the concept that epoprostenol, while having no effect on the normal pulmonary circulation, acts on the hypertensive circulation via a mechanism that may result in a delayed alteration of vasoconstrictor/vasodilator balance.

Beneficial effect of an oral analog of prostacyclin on pulmonary hypertension secondary to congenital heart disease

1998 ◽  
Vol 8 (2) ◽  
pp. 205-210 ◽  
Author(s):  
Fukiko Ichida ◽  
Kei-ichiro Uese ◽  
Shin-ichi Tsubata ◽  
Ikuo Hashimoto ◽  
Yuji Hamamichi ◽  
...  
Keyword(s):  
Nitric Oxide ◽  
Congenital Heart Disease ◽  
Pulmonary Hypertension ◽  
Heart Disease ◽  
Congenital Heart ◽  
Hemodynamic Effect ◽  
Pulmonary Vasodilation ◽  
Beraprost Sodium ◽  
Hypertension In Children ◽  
Appreciable Reduction

AbstractTo determine whether a newly synthesized oral analog of prostacyclin, called beraprost sodium, could cause pulmonary vasodilation, we studied its hemodynamic effect on pulmonary hypertension of children, comparing it to other vasodilatory agents, such as nitric oxide and tolazoline. We studied 20 children (mean age 24 months) having pulmonary hypertension secondary to congenital heart disease. A single oral dose of beraprost sodium resulted in an appreciable reduction of pulmonary vascular resistance (mean 34%), which was comparable to that induced by inhalation of nitric oxide and intravenous delivery of tolazoline (mean 41% and 31%, respectively). The results suggest that beraprost sodium may serve as a novel and safe vasodilator for the screening of pulmonary vasoreactivity, as well as the treatment of pulmonary hypertension in children.

Association of nitric oxide dose and methemoglobin levels in patients with congenital heart disease and pulmonary hypertension

2002 ◽  
Vol 90 (4) ◽  
pp. 442-444 ◽  
Author(s):  
Elise M Riddle ◽  
Timothy F Feltes ◽  
Kerry Rosen ◽  
J.Kennard Fraley ◽  
Antonio R Mott ◽  
...  
Keyword(s):  
Nitric Oxide ◽  
Congenital Heart Disease ◽  
Pulmonary Hypertension ◽  
Heart Disease ◽  
Congenital Heart
Sign in / Sign up

Export Citation Format

Share Document